

QUANTITATIVE APPROACH TO ASSIST NEUROBLASTOMA ASSESSMENT BY MEASURING I-123 mIBG UPTAKE IN SCINTIGRAPHIC IMAGES

RAFAEL MARTÍNEZ-DÍAZ[✉],¹ JULIA BALAGUER², LUIS MANUEL SÁNCHEZ RUIZ¹, PILAR BELLO³, VICTORIA CASTEL⁴, ANTONIO RIVAS³, ADELA CAÑETE², MARINA FALGAS³, JOSE LUIS LOAIZA³ AND GUILLERMO PERÍS-FAJARNÉS¹

¹Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain; ²Hospital La Fe, Paediatric Oncology Unit, Bulevar Sur s/n, 46026 Valencia, Spain; ³Hospital La Fe, Nuclear Medicine Unit, Bulevar Sur s/n, 46026 Valencia, Spain; ⁴Hospital La Fe, Health Research Institute, Bulevar Sur s/n, 46026 Valencia, Spain
e-mail: rmartin@upv.es, julbagui@yahoo.es, lmsr@mat.upv.es, bello_pil@gva.es, castel_vic@gva.es, rivas_ant@gva.es, canyete_ade@gva.es, marinafalgas@gmail.com, loaiza_joseluis@hotmail.com, gperis@upv.es
(Received September 11, 2014; revised November 14, 2014; accepted January 27, 2015)

ABSTRACT

Whole-body ¹²³I-Metaiodobenzylguanidine (mIBG) scintigraphy is used as the primary image modality in neuroblastoma detection. It is the most sensitive and specific method for staging and response evaluation. Validated semi-quantitative scoring methods with low interobserver variability and high reproducibility have shown to be indispensable for the evaluation of response to therapy. However, low resolution, noise and acquisition difficulties, specially in children, make low definition scans. These facts increase observer dependent interpretations that limit assessment and complicate to put a scoring method successfully into practice. It is essential to have an objective and reliable measure of response to test the activity of therapies. In this paper we propose the use of a quantitative observer-independent measurement of the strength of uptake to be used as an additional tool for assisting the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) semi-quantitative scoring method. This is the scoring method recommended by the SIOPEN Nuclear Medicine and Physics Committee, in collaborative work with the Children's Oncology Group, as the standard one for acquiring and reporting diagnostic paediatric mIBG scans across Europe. Our proposed method is based on the ratio between the amount of specific uptake at tumours and the amount of non-specific uptake at SIOPEN anatomical sectors which has shown to be constant in all the scans of the patients.

Keywords: image analysis, mIBG, neuroblastoma, quantitative assessment, scintigraphy.

INTRODUCTION

Neuroblastoma stands out among paediatric solid tumours because of its relative frequency. It is the third most common malignant solid tumour of childhood (Mueller *et al.*, 2013) and it is metastatic in half of the patients at diagnosis, making accurate evaluation of metastatic sites challenging (Matthay *et al.*, 2010). Anatomic imaging methods, such as computerized tomography (CT) and magnetic resonance imaging (MRI), are most useful for evaluation of the primary tumour mass and nearby involved lymph nodes. Functional imaging radioactive tracers, such as ¹²³I-mIBG, ¹⁸F-FDG, and ^{99m}Tc-MDP, are used to assess the extent of disease and to search for distant metastases (Sharp *et al.*, 2013).

¹²³I-mIBG scintigraphy remains the most specific and sensible imaging modality of staging and response evaluation (virtually 100% of specificity) (Charron, 2013). It is essential in the management of neuroblastoma. mIBG enters neuroendocrine cells

by an active uptake mechanism via the epinephrine transporter and is stored in the neurosecretory granules, resulting in a specific concentration in contrast to cells of other tissues.

The pathological distribution of ¹²³I-mIBG is described as uptake in the primary tumour and in the metastatic sites (Bombardieri *et al.*, 2010). High peaks of intensity are to be observed at location of ¹²³I-mIBG avid tissues. This is called specific uptake. Non-specific uptake is also observed at the whole body as a light homogeneous uptake pattern without peaks. It is due to the ¹²³I-mIBG travelling in the bloodstream until it is excreted.

In order to evaluate the prognostic effects and quantify efficacy of therapy, numerous semi-quantitative scores have emerged (Ady *et al.*, 1995; Frappaz *et al.*, 2000; Messina *et al.*, 2006; Lewington *et al.*, 2009; Yanik *et al.*, 2013; Decarolis *et al.*, 2013) although none of them has shown to be superior to the others for quantification of response to the

treatment (Matthay *et al.*, 2010). In 2004, nuclear medicine physicians and oncologists of the major cooperative groups from North America, Australia, New Zealand, Europe, China and Japan formed the International Neuroblastoma Risk Group (INRG). One of INRG's goals was to reach international consensus for standardized procedures for performing and scoring ^{123}I -mIBG scans to minimize subjective assessments and improve the concordance between readers. The use of a semi-quantitative score has shown to be essential for evaluation of the efficacy of therapy (Brisse *et al.*, 2011).

All these methods divide the skeleton into anatomical sectors, then give each sector an individual score for number of metastatic sites and strength of uptake. They have achieved good correlation with outcome. Intensity at uptake sites is usually scored as doubtful, definite, obvious or strong based upon the observer assessment in comparison to liver or other soft tissues.

But ^{123}I -mIBG images have low definition, specially in paediatric neuroblastoma. Consecutive scans from the same patient may display variations of intensity. This is caused by a number of factors such as changes in the accumulation of radioisotopes during each examination, changes in the gamma camera, the volume of water intake, patient motion, the amount of urine excreted or the response to treatment. In addition, noise is also an important factor degrading scintigraphic images (Hannequin and Mas, 2002; Krom *et al.*, 2013).

These factors limit the successful application of the scoring methods, although they are diminished by strictly following the standardized guidelines for preparing the patient for the acquisition process defined in (Bombardieri *et al.*, 2010). In Spain, La Fe Hospital is the center of reference for neuroblastoma and it is trying to institute the semi-quantitative scoring method recommended for the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN; Lewington *et al.*, 2009; 2011; Ladenstein *et al.*, 2011) for neuroblastoma management. This method is being developed by the Nuclear Medicine and Physics Committee, in collaborative work with the Children's Oncology Group, for acquiring, reading and scoring paediatric mIBG scans. This collaborative group is setting the standards for the paediatric MIBG scans across Europe. The problems arise when image definition is poor. The disappearance or decreased intensity of a lesion could be very subjective in such cases and then intensity measurements show low concordance between different observers.

It is possible that response to therapy exists although it is too light to be visible for the human eye.

On the other hand, it is possible to have a light increase in uptake at a new metastatic site but not high enough to be clearly identified.

An objective measurement between specific uptake at the regions of interest (ROIs) such as tumours, metastases, *etc.* and non-specific uptake at a region of reference is needed. It could lead to a better identification and stratification of the cases.

First observer independent attempts to quantify uptake in ROIs in scintigraphies were made in (Maisey *et al.*, 1973) where an uptake measurement of ^{99m}Tc in thyroid studies based on the number of gamma photons detected (counts) was proposed. The main idea was to calculate the ratio between counts in ROI and the total body counts.

This idea is used in heart-to-mediastinal (H/M) uptake ratio derived from mIBG scintigraphy by providing a quantitative measurement of uptake with success to monitor response to medical treatment in cardiac sympathetic imaging (Inoue *et al.*, 2013). The H/M ratio is in widespread use, however, there are variations among publications from various institutions because of several factors (Chen *et al.*, 2011; Bulten *et al.*, 2012), especially, the way the ROIs are placed.

Computer-aided applications for automatic assessment of ^{99m}Tc bone scintigraphic images have been developed as well. In them, brightness is used with success for feature identification. For instance, in Yin and Chiu (2004), local maximum of brightness in bones and its asymmetries are used to detect abnormalities in skeleton in ^{99m}Tc whole body bone scintigraphies.

Later in Jia-Yann *et al.* (2007), a set of algorithms was also proposed for segmentation and lesion grey level determination in ^{99m}Tc whole body bone scintigraphies. In this work, after smoothing noise and segmenting skeleton, the lesion grey level is used as an evidence of the existence of uptake. They used a set of previous measurements of pixel's intensity mean and standard deviation at different body parts in a set of 100 patients to create a grey level of reference. Then, any ROI could be measured in another patient and compared with the estimated normal grey level. The larger the standard deviation value of grey level is at a given region, the greater the possibility of bone lesion existence is.

^{99m}Tc and ^{123}I -mIBG are similar scintigraphic procedures and in both brightness is the primary tool used for abnormal region identification. Nevertheless, images obtained in ^{99m}Tc scans are very different from ^{123}I -mIBG due to a combination of diverse factors,

the most important of which being that different radiopharmaceuticals have different biodistributions. For instance, previous work on bone segmentation with ^{99m}Tc bone scintigrams in Sajn *et al.* (2005) based on detecting edges is not applicable as a general rule in paediatric neuroblastoma ^{123}I -mIBG scintigraphies because bones are not always visible. Skeletal uptake is only visible in neuroblastoma in those patients with bone metastases. Thus, a quantitative measurement method that works even when no bones are visible in scan is required.

This brings out that application of techniques to improve image quality such as image enhancement based on histogram with successful application in detection of lesions in ^{99m}Tc scintigraphies Jeong *et al.* (2011) seems not being useful in ^{123}I -mIBG of children in neuroblastoma detection. In Wesolowski *et al.* (2005), although the Poisson noise level was reduced, nuclear medicine physicians preferred original (not processed) planar images rather than the processed version due the blur effect on features and general image degradation.

As a result of the above, the algorithms successfully used in ^{99m}Tc are not directly applicable in ^{123}I -mIBG. Nevertheless, the use of pixel's intensity mean and standard deviation at different body parts is also useful in ^{123}I -mIBG. In Martínez-Díaz *et al.* (2013), an observer independent method for measuring the uptake level in any body region was introduced. The technique enables the measurement of the relative amount of uptake with a quantitative unit based on the ratio between uptake at neuroblastoma tumours and metastases and the rest of the tissues.

In this paper, we analyse the use of this observer independent computerized procedure for the measurement of the strength of uptake as an additional tool to assist the SIOPEN semi-quantitative scoring method. Our approach is based on the ratio between the specific uptake at tumours or metastases and the non-specific constant uptake threshold of the rest of tissues at the SIOPEN body sector where a tumour is located. Regional comparison of uptake at tumour to uptake at predefined areas, such as the SIOPEN anatomical sectors, instead of the comparison to the local lesion site facilitates the repetitiveness of the process as it sets a fixed point of reference that helps in eliminating observer dependent variabilities.

This paper is structured as follows. In section Materials and Methods, we detail the proposed application of the measurement method defined in Martínez-Díaz *et al.* (2013) in the anatomical division defined by the SIOPEN semi-quantitative scoring method (Lewington *et al.*, 2009; 2011; Ladenstein

et al., 2011). Experimental results are provided in section Results, followed by discussion of the results in section Discussion and conclusions being drawn in section Conclusions.

MATERIALS AND METHODS

The experimental set contains twenty-seven ^{123}I -mIBG scintigraphies of 10 patients under 14 years old, labeled PA_1 to PA_{10} , suffering from neuroblastoma. Images were acquired at La Fe Hospital by its Nuclear Medicine Unit following the standardized guidelines described in (Bombardieri *et al.*, 2010) after a slow intravenous injection of ^{123}I -mIBG (Dose: $100 \mu\text{Ci/Kg}$) and using different scintillation cameras set to a photopeak equal to the principal gamma photon emitted, that is, of 159 keV. A minimum of 250 000 and a maximum of 500 000 photon counts were obtained for each anterior and posterior views. The use of these scintigraphies for this study was approved by the La Fe Hospital's Biomedical Research Ethics Committee.




Fig. 1. SIOPEN semi-quantitative scoring method divides the skeleton into 12 anatomic segments as shown. On the central images, anterior views of patient PA_2 taken at pre chemotherapy time T_1 , and at time T_2 after it, with the sectors of the anatomic division made for our analysis. On the right, image with only the body frame I_{BF} created from the 12 sectors extracted from scan T_2 .

The scan produces two planar images, the anterior and the posterior views. For every patient we have a scintigraphy in time T_1 pre chemotherapy and another one post it in time T_2 . For some patients we have more scans, for example for patient PA_4 , we have four successive scans T_1 to T_4 . The group of ^{123}I -mIBG scans from each patient were interpreted by the nuclear medicine physicians of La Fe Hospital following current guidelines in (Bombardieri *et al.*, 2010).

This assessment is made in terms of description of the position of the lesions when they are visible on a given scan and, in consecutive scans of same patient, for each lesion previously detected, they include whether, in their appraisal, the lesion is more or less intense than in previous scans or if it is not visible any longer.

In planar image, the objective evidence of a tumour or metastasis is a peak of counts compared with local area counts average. For instance, tumours labeled as ROI_1, ROI_2, ROI_3 and ROI_4 in the series of scintigraphies shown in Fig. 2 are visible because of the high number of photons detected at their exact positions, greater than the average in the surroundings of tumours. Instead of using the surroundings of each tumour, that could be observer-dependent, we will test the use of each anatomical sector defined by the SIOPEN method as the predefined area for computing that local area counts average of reference for every ROI inside it.

In both views of every test scintigraphy, patient's body SIOPEN sectors (Lewington *et al.*, 2009; 2011; Ladenstein *et al.*, 2011) are identified in an image by placing a rectangle to delimit them: skull, thoracic cage, proximal right upper limb, distal right upper limb, proximal left upper limb, distal left upper limb, spine, pelvis, proximal right lower limb, distal right lower limb, proximal left lower limb and distal left lower limb as shown in Fig. 1. Then we split the original scintigraphy into 12 images identified as I_1, I_2, \dots, I_{12} , one for each subimage of each sector in the original scan. We do that on both views.

We identify the image of the whole trunk as I_T which is the union of SIOPEN Sectors 2 and 8 (see Figs. 1 and 2). We will use I_T in order to facilitate taking measurements of uptake at the liver, where uptake is usually present, and to compare it with measurements of uptake at tumours or other ROIs in trunk. We also define I_{BF} as the image of the body frame formed by extracting the subimages of all the SIOPEN sectors from original scintigraphy. I_{BF} is a new image of the same size as the original scan which only contains patient's body sectors and the rest of the image is blank.

The liver and each tumour and metastatic region identified by physicians of each patient are assigned to the SIOPEN sector where they are located. For each of them, we label regions as $\{Liver, ROI_1, \dots, ROI_{N_i}\}$, where N_i is the number of ROIs at each specific patient i , $1 \leq i \leq 10$.




Fig. 2. I_T sectors of scans of patient PA_4 in time T_1 to T_4 with ROIs selected inside circles labeled from 1 to 4. On top, anterior I_T views and on bottom the posterior ones.

Let x_{ij} be the intensity (number of photon counts) at coordinates (i, j) in any body sector I_k with $k \in \{1, 2, \dots, 12, T, BF\}$ that represents radionuclide uptake by tissue at these coordinates. We denote by \bar{I}_k and σ_{I_k} the average and standard deviation of I_k respectively. In order to compare the count value x_{ij} at pixel $(i, j) \in I_k$ with count value x'_{ij} at same patient's body coordinates in successive scintigraphies, we need both values transformed into the same uptake scale.

We will transform the number of photons counted at each pixel x_{ij} into its Z-Score value $Z_{I_k}(i, j)$ in reference to its SIOPEN sector counts average \bar{I}_k which will allow us to take objective and comparable uptake measurements,

$$Z_{I_k}(i, j) = \frac{x_{ij} - \bar{I}_k}{\sigma_{I_k}}. \quad (1)$$

The brighter the pixels in the tumour are, the further they are above the average of sector \bar{I}_k . So our interest must focus in singling out those x_{ij} values that are greater than \bar{I}_k because they are very relevant uptake points. Consequently, we will use the transformation of Eq. 1 as in (Martínez-Díaz *et al.*, 2013) but now applied to each SIOPEN sector:

$$Q_{I_k}(i, j) = \max(Z_{I_k}(i, j), 0). \quad (2)$$

For the uptake measurement method to work properly, it is important to take into account only those pixels of image which unambiguously belong to the

body frame, discarding pixels off the frame which have a value x_{ij} whose origin is unknown (noise outside body frame).

For each image I_k , we denote by \bar{Z}_{I_k} the average of $\{Z_{I_k}(i, j) : (i, j) \in I_k\}$ and by \bar{Q}_{I_k} the average of $\{Q_{I_k}(i, j) : (i, j) \in I_k\}$. Z_{I_k} transforms I_k values into a new scale with zero mean and one as standard deviation. When applied to a data of a normal distribution, \bar{Z}_{I_k} is defined by

$$\frac{1}{\sqrt{2\pi}} \int_{-\infty}^{\infty} x e^{-x^2/2} dx = 0,$$

and \bar{Q}_{I_k} , the average of the normalized values of those original values which were above the original average is a constant that could be calculated as

$$\begin{aligned} \frac{1}{\sqrt{2\pi}} \int_{-\infty}^{\infty} u(x) x e^{-x^2/2} dx &= \frac{1}{\sqrt{2\pi}} \int_0^{\infty} x e^{-x^2/2} dx \\ &= 0.39894, \end{aligned}$$

where $u(x)$ is the Heaviside step function.

This means that, on average, the values that are above the mean have a normalized value of 0.39894 which we round to 0.40. This value is a threshold of reference for the intensity. Any point with a value greater than of 0.40 has a value abnormally high in its sector.

With these prerequisites we are able to take objective measurements at the image of any region inside a SIOOPEN sector and compare them with the next scintigraphies of the same patient. We will test the use of \bar{Q}_{I_k} as the threshold of reference of specific uptake (tumour or metastases) at each SIOOPEN sector and at I_T . We will test as well the use of $\bar{Z}_{I_{BF}}$ as a reference for comparing any region between different scintigraphies.

We are interested in taking measurements of the regions with specific uptake previously identified by physicians and of other predefined areas such as the liver. These measurements of the liver are used in semi-quantitative scoring methods as a reference for the specific uptake.

In Martínez-Díaz *et al.* (2013), the next expression was introduced for measuring any $ROI_{\#}$ of the image. We adapt it for taking measurements in reference to the SIOOPEN sector where the ROI is located:

$$\bar{Q}_{I_k}(ROI_{\#}) = \frac{\sum \{Q_{I_k}(i, j) : (i, j) \in ROI_{\#}\}}{Cd(ROI_{\#})}, \quad (3)$$

where $Cd(ROI_{\#})$ denotes the number of elements of $ROI_{\#}$ and $k \in \{1, \dots, 12, T, BF\}$.

$\bar{Q}_{I_k}(ROI_{\#})$ always takes positive values and it quantifies how higher $ROI_{\#}$ is above the average of counts \bar{I}_k of the SIOOPEN sector k where it is located.

In order to assist staff in taking an objective and repeatable measurement of a given $ROI_{\#}$, at the moment of putting Eq. 3 into practice, it is important to unambiguously identify the exact points belonging to that $ROI_{\#}$.

As main evidence of tumour is the peak of counts, points unambiguously belonging to it are bound to be closer to the maximum intensity at the body area where it is located.




Fig. 3. Example of the process of taking quantitative measurements of any ROI in patients PA_1, PA_2, PA_6 and PA_7 . Each ROI is demarcated inside a rectangle ($W_{ROI_{\#}}$) close-fitted to it. Results are shown in Table 3.

Formally, assuming a given $ROI_{\#}$ is located within a SIOOPEN sector I_k , we denote by $W_{ROI_{\#}}$ a rectangle around the whole $ROI_{\#}$, and only that $ROI_{\#}$, where it is included (see Fig. 3). This rectangle should be placed close-fitted to the shape of the $ROI_{\#}$. If point at coordinates $(i, j) \in W_{ROI_{\#}}$ belongs to that ROI, then intensity $x_{ij} \in [X_{ROI_{\#}thres}, X_{ROI_{\#}max}]$ where $X_{ROI_{\#}max}$ is the maximum value for intensity in $W_{ROI_{\#}}$ and $X_{ROI_{\#}thres}$ with $X_{ROI_{\#}thres} < X_{ROI_{\#}max}$ is the value of the minimum intensity for the $ROI_{\#}$. Consequently, we consider the following $ROI_{\#}$ membership set:

$$ROI_{\#} = \{\forall (i, j) \in W_{ROI_{\#}} : x_{ij} \in [X_{ROI_{\#}thres}, X_{ROI_{\#}max}]\}. \quad (4)$$

The value of $X_{ROI_{thres}}$ is unknown. As an approximation, we could consider it in reference to $X_{ROI_{max}}$. This will lead us to a more observer independent measurement. For instance, we could fix $X_{ROI_{thres}} = 0.75X_{ROI_{max}}$. For simplicity, we will follow the criterion of selecting it equal to the minimum intensity in $W_{ROI_{\#}}$. In practice, this will lead to different measurements of the same $ROI_{\#}$ depending on the placement of $W_{ROI_{\#}}$ so that it should be close-fitted to the shape of it.

Besides measuring $\bar{Q}_{I_k}(ROI_{\#})$, in our tests we also take measurements of the normalized $Z_{I_k}(i, j)$ values of the points belonging to the $ROI_{\#}$. We define $\bar{Z}_{I_k}(ROI_{\#})$ as

$$\bar{Z}_{I_k}(ROI_{\#}) = \frac{\sum \{Z_{I_k}(i, j) : (i, j) \in ROI_{\#}\}}{Cd(ROI_{\#})}, \quad (5)$$

where $Cd(ROI_{\#})$ denotes the number of elements of the $ROI_{\#}$ and $k \in \{1, \dots, 12, T, BF\}$.

$\bar{Z}_{I_k}(ROI_{\#})$ takes positive and negative values. Negative measurements indicate that points in the selected $ROI_{\#}$ have lower values in average than \bar{I}_k . Positive measurements indicate the contrary.

In order to take objective measurements of any region of the body and to compare it to any other region located in any body part of the same or other scan, we should use the measurement related to the body frame I_{BF} , that is, $\bar{Z}_{I_{BF}}(ROI_{\#})$.

Hence for every $ROI_{\#}$ we can take quantitative measurements with respect to the SIOPEN sector where it is located as well as to the whole body frame I_{BF} .

In case a tumour is visible in both views, it has two measurements, one referenced to \bar{I}_k of the anterior view and the one referenced to the posterior view, as shown in Fig. 2.

RESULTS

Table 1 collects Sectors \bar{Q}_{I_k} and \bar{Z}_{I_k} example measurements in test patient PA_2 shown in Fig. 1. At both scans, T_1 pre-therapy and T_2 post it, reference values are similar at both views and close to the expected values 0.40 and 0.00. Similar results were observed in the whole test set as shown in Fig. 4 where the trunk sectors I_T of patients PA_2, PA_4 and PA_5 are shown as an example. Although the radiodistribution is very different in each patient, the values \bar{Z}_{I_T} and \bar{Q}_{I_T} are similar in every one as expected.

Table 2 shows a comparison between quantitative measurements and qualitative inform in patient PA_4

(Fig. 2). \bar{Z}_{I_T} and $\bar{Z}_{I_{BF}}$ values are 0.00 in all the four PA_4 scans T_1 to T_4 although they presented variations in the intensity average \bar{I}_T . Each $\bar{Q}_{I_T}(ROI_{\#})$ along the series of PA_4 is an objective evidence of tumour uptake evolution. $\bar{Q}_{I_T}(ROI_{\#})$ and $\bar{Z}_{I_T}(ROI_{\#})$ measurements correlate well with qualitative ranks (visible or not, more or less intense, etc.) giving precise information of uptake change, that is, a positive increment when the peak is more intense and negative on the contrary. What is more, quantitative measurements $\bar{Q}_{I_T}(ROI_{\#})$ give more intuitive information about the amount of uptake in tumours in reference to local sector counts average \bar{I}_T . Values of $\bar{Q}_{I_T}(ROI_{\#})$ close to 0.00 imply light almost not visible uptake. Values from 0.00 to 0.40 mean higher but still light uptake in comparison to the count average \bar{I}_T . Finally, values of $\bar{Q}_{I_T}(ROI_{\#})$ greater than 0.40 belong to a high uptake $ROI_{\#}$, abnormally higher than expected in sector, in comparison to \bar{I}_T .

Table 1. *Example of \bar{Q}_{I_k} and \bar{Z}_{I_k} , $k \in \{1, 3, \dots, 12, T, BF\}$ sector measurements in test patient PA_2 shown in Fig. 1. Succesive scans T_1 , pre chemotherapy, and T_2 , post it. Both reference values are similar, on both sides, and close to expected values 0.40 and 0.00, respectively. Similar results were observed in the whole test set.*

| PA_2 | PA_2 measurements | | | |
|--------------------|---------------------|-------------|-------------|-------------|
| | T_1 | T_2 | | |
| | Anterior | Posterior | Anterior | Posterior |
| \bar{Q}_{I_1} | 0.39 | 0.38 | 0.38 | 0.39 |
| \bar{Z}_{I_1} | -0.02 | -0.03 | -0.02 | -0.02 |
| \bar{Q}_{I_T} | 0.40 | 0.40 | 0.40 | 0.40 |
| \bar{Z}_{I_T} | 0.00 | 0.00 | 0.00 | 0.00 |
| \bar{Q}_{I_3} | 0.40 | 0.39 | 0.39 | 0.40 |
| \bar{Z}_{I_3} | 0.00 | 0.00 | 0.00 | 0.00 |
| \bar{Q}_{I_4} | 0.40 | 0.39 | 0.40 | 0.40 |
| \bar{Z}_{I_4} | 0.00 | 0.00 | 0.00 | 0.00 |
| \bar{Q}_{I_5} | 0.40 | 0.36 | 0.39 | 0.40 |
| \bar{Z}_{I_5} | 0.00 | 0.00 | 0.00 | 0.00 |
| \bar{Q}_{I_6} | 0.40 | 0.38 | 0.40 | 0.39 |
| \bar{Z}_{I_6} | 0.00 | 0.00 | 0.00 | 0.00 |
| \bar{Q}_{I_9} | 0.38 | 0.39 | 0.40 | 0.40 |
| \bar{Z}_{I_9} | 0.00 | 0.00 | 0.00 | 0.00 |
| $\bar{Q}_{I_{10}}$ | 0.40 | 0.39 | 0.40 | 0.39 |
| $\bar{Z}_{I_{10}}$ | 0.00 | 0.00 | 0.00 | 0.00 |
| $\bar{Q}_{I_{11}}$ | 0.33 | 0.35 | 0.33 | 0.32 |
| $\bar{Z}_{I_{11}}$ | 0.00 | 0.00 | 0.00 | 0.00 |
| $\bar{Q}_{I_{12}}$ | 0.33 | 0.35 | 0.38 | 0.35 |
| $\bar{Z}_{I_{12}}$ | 0.00 | 0.00 | 0.00 | 0.00 |
| $\bar{Q}_{I_{BF}}$ | 0.39 | 0.40 | 0.36 | 0.39 |
| $\bar{Z}_{I_{BF}}$ | 0.00 | 0.00 | 0.00 | 0.00 |

DISCUSSION

One of the big problems of all the existing mIBG scores is the subjectivity of the interpretation of the scans that makes very difficult the quantitation of the response to treatment. Our series of patients, can be considered as a pilot demonstration of the possibility of truly quantify the extension of disease at diagnosis and the response to treatment, avoiding inter-observer variations.

In every analyzed ^{123}I -mIBG of test set, the mean of the standard Z-Score \bar{Z}_{I_k} for any SIOOPEN body sector I_k as well as $\bar{Z}_{I_{BF}}$ tends to be constant with value close to 0.0. This fact enables us to take comparable measurements with respect to the local counts average at any SIOOPEN sector I_k . \bar{Z}_{I_k} and $\bar{Z}_{I_{BF}}$ equal to 0.00

is the common point of reference between scans of the same patient, and even between different patients. Regional comparisons to the predefined SIOOPEN sectors rather than to local lesion site reduces observer dependent measurements.

In the same patient and the same scan, comparisons between measurements $\bar{Z}_{I_k}(ROI_{\#})$ taken at ROIs of same sector I_k are direct. For instance, objective comparison between the specific uptake $\bar{Z}_{I_k}(ROI_{\#})$ due to a possible tumour and non-specific uptake at liver $\bar{Z}_{I_k}(Liver)$ is possible.

Comparisons between ROIs located in different SIOOPEN sectors by using $\bar{Z}_{I_k}(ROI_{\#})$ and $\bar{Z}_{I_{k'}}(ROI_{\#'})$ could be deceptive in such cases where one of the sectors has an abnormal counts increase, for instance, due to a whole sector ^{123}I -mIBG stain in skin.

Table 2. Comparison between qualitative informs (visible or not, more or less intense, etc.) and quantitative measurements of tumours in posterior views of scans T_1 and T_2 (quantitative difference in parentheses) of patient PA_4 (Fig. 2). $\bar{Z}_{I_{BF}}$ and \bar{Z}_{I_T} are 0.0 at every scintigraphy. Both references enable to take quantitative comparisons of uptake between scintigraphies. $\bar{Q}_{I_{BF}}$ and \bar{Q}_{I_T} are close to 0.40 at each scan as expected. This is a reference for comparisons to local sector average. Values of $\bar{Q}_{I_T}(ROI_{\#})$ higher than 0.40 (\bar{Q}_{I_T}) means that the $ROI_{\#}$ has an abnormal value of counts, higher than the average of the trunk sector I_T .

| PA_4 measurements | | | | |
|---------------------------|-------------|---------------|-------------------|--------------------|
| PA_4 | T_1 | T_2 | T_3 | T_4 |
| \bar{I}_T | 0.29 | 0.40 | 0.16 | 0.29 |
| \bar{Z}_{I_T} | 0.00 | 0.00 | 0.00 | 0.00 |
| \bar{Q}_{I_T} | 0.39 | 0.40 | 0.38 | 0.39 |
| $\bar{Z}_{I_{BF}}$ | 0.00 | 0.00 | 0.00 | 0.00 |
| $\bar{Q}_{I_T}(Liver)$ | 0.92 | 0.95 | 0.78 | 1.09 |
| $\bar{Z}_{I_T}(Liver)$ | 0.84 | 0.86 | 0.67 | 1.05 |
| $\bar{Z}_{I_{BF}}(Liver)$ | 1.59 | 1.59 | 1.41 | 1.84 |
| Qualitative | Visible | Not visible | Not Visible | Not Visible |
| $\bar{Q}_{I_T}(ROI_1)$ | 0.40 | 0.05 (-0.35) | 0.03 (-0.02) | 0.00 (-0.03) |
| $\bar{Z}_{I_T}(ROI_1)$ | 0.11 | -0.56 (-0.67) | -0.62 (-0.06) | -0.71 (-0.09) |
| $\bar{Z}_{I_{BF}}(ROI_1)$ | 0.76 | 0.00(-0.76) | -0.07 (-0.07) | -0.16(-0.09) |
| Qualitative | Visible | Not visible | More Intense | Less Intense |
| $\bar{Q}_{I_T}(ROI_2)$ | 0.38 | 0.23 (-0.15) | 0.90 (+0.67) | 0.73 (-0.17) |
| $\bar{Z}_{I_T}(ROI_2)$ | 0.19 | 0.01(-0.18) | 0.72 (+0.71) | 0.66 (-0.06) |
| $\bar{Z}_{I_{BF}}(ROI_2)$ | 0.85 | 0.64 (-0.21) | 1.23 (+0.59) | 1.12 (-0.11) |
| Qualitative | Visible | Not visible | Not Visible | Not Visible |
| $\bar{Q}_{I_T}(ROI_3)$ | 0.05 | 0.00 (-0.05) | 0.00(\approx) | 0.00(\approx) |
| $\bar{Z}_{I_T}(ROI_3)$ | -0.61 | -0.79 (-0.18) | -0.87 (-0.08) | -0.81(+0.06) |
| $\bar{Z}_{I_{BF}}(ROI_3)$ | -0.06 | -0.26 (-0.20) | -0.35(-0.09) | -0.27(+0.08) |
| Qualitative | Visible | Not visible | Not Visible | Not Visible |
| $\bar{Q}_{I_T}(ROI_4)$ | 0.06 | 0.00 (-0.06) | 0.02 (+0.02) | 0.02 (\approx) |
| $\bar{Z}_{I_T}(ROI_4)$ | -0.47 | -0.68 (-0.21) | -0.67(+0.01) | -0.63(+0.04) |
| $\bar{Z}_{I_{BF}}(ROI_4)$ | 0.10 | -0.14 (-0.24) | -0.13(+0.01) | -0.06 (+0.07) |




| ¹²³ I-mIBG | P ₂ T ₁ | P ₄ T ₁ | P ₅ T ₁ |
|-----------------------|---|---|---|
| Original |  |  |  |
| \bar{Q}_{I_T} | 0.40 | 0.39 | 0.40 |
| \bar{Z}_{I_T} | 0.00 | 0.00 | 0.00 |

Fig. 4. Example of sector I_T measurements in patients PA_2 , PA_4 and PA_5 . Although the radiodistribution is very different in each patient, the value of \bar{Z}_{I_T} is close to 0.00 and \bar{Q}_{I_T} is close to 0.40 in all of them. Same results were observed in the whole test set.

In order to properly compare ROIs at different sectors, the value of $\bar{Z}_{I_{BF}}(ROI_{\#})$ of each ROI may be used. The whole body counts average \bar{I}_{BF} is used as the numeric reference for taking quantitative measurements in the same way that it is already a visual implicit reference for the human eye for the qualitative assessment.

What is more, comparisons between non-specific background uptake at any SIOPEN sector $\bar{Z}_{I_{BF}}(I_k)$ with respect to the whole body frame $\bar{Z}_{I_{BF}}$ are also possible. At limb sectors, for instance at Sector 9, $\bar{Z}_{I_{BF}}(I_9)$ measurement should be low in patients with no metastatic sites at that sector. The increase of this objective metric is an evidence of an abnormal uptake at this sector with respect to the whole body, that is, a possible metastatic site in bones.

This fact makes $\bar{Z}_{I_{BF}}(ROI_{\#})$ a good candidate to take standardized comparable measurements between different patients and different scans. A database of usual $\bar{Z}_{I_{BF}}(ROI_{\#})$ values of tumour and metastases at each SIOPEN sector could be used for comparisons in cases of doubt.

Quantitative measurements $\bar{Q}_{I_k}(ROI_{\#})$ and the fact that \bar{Q}_{I_k} is always close to 0.40 gives an intuitive visual reference value of how intense is that ROI in reference to the local counts average \bar{I}_k .

The use of $\bar{Q}_{I_{BF}}(ROI_{\#})$ could be problematic because it takes only positive values and it is related to \bar{I}_{BF} . It is possible for a given ROI to be greater than the average at its sector but lower than \bar{I}_{BF} and then $\bar{Q}_{I_{BF}}(ROI_{\#})$ would be 0.0. In such cases, the value of $\bar{Z}_{I_{BF}}(ROI_{\#})$ would be negative meaning that the ROI has a counts average lower than the average at the whole body frame I_{BF} .

These results show that the use of $\bar{Q}_{I_k}(ROI_{\#})$ and $\bar{Q}_{I_{BF}}(ROI_{\#})$ could be useful for automatic detection of abnormal uptake regions on image. If any region in body has a value greater than $\bar{Q}_{I_{BF}}$ then it is bound to be abnormal, because it is much too intense. $\bar{Q}_{I_k}(ROI_{\#})$ could be used in the same manner.

Table 3. Results of measurements in anterior views of scans of patients PA_2 and PA_6 in Fig. 3. Comparisons between different patients are possible by using $\bar{Z}_{I_{BF}}(ROI_{\#})$ because it is referenced to body frame counts average \bar{I}_{BF} and $\bar{Z}_{I_{BF}}$ has a value of 0.0 in every scan of every patient.

| PA ₂ and PA ₆ measurements | | |
|--|----------------|----------------|
| PA ₂ | T ₁ | T ₂ |
| \bar{Z}_{I_1} | 0.00 | 0.00 |
| $\bar{Z}_{I_{BF}}$ | 0.00 | 0.00 |
| Qualitative | Not visible | Visible |
| $\bar{Q}_{I_1}(ROI_1)$ | 0.05 | 0.14 (+0.09) |
| $\bar{Z}_{I_1}(ROI_1)$ | -0.53 | -0.43 (+0.10) |
| $\bar{Z}_{I_{BF}}(ROI_1)$ | -0.56 | -0.52 (+0.04) |
| Qualitative | Not visible | Visible |
| $\bar{Q}_{I_T}(ROI_2)$ | 0.00 | 0.53 (+0.53) |
| $\bar{Z}_{I_T}(ROI_2)$ | -0.84 | 0.15(+0.91) |
| $\bar{Z}_{I_{BF}}(ROI_2)$ | -0.30 | 1.01(+1.31) |
| Qualitative | Not visible | Visible |
| $\bar{Q}_{I_{12}}(ROI_3)$ | 0.64 | 0.90 (+0.26) |
| $\bar{Z}_{I_{12}}(ROI_3)$ | 0.39 | 0.75 (+0.36) |
| $\bar{Z}_{I_{BF}}(ROI_3)$ | -0.80 | -0.57 (+0.23) |
| PA ₆ | T ₁ | T ₂ |
| \bar{Z}_{I_1} | 0.00 | 0.00 |
| $\bar{Z}_{I_{BF}}$ | 0.00 | 0.00 |
| Qualitative | Not visible | Visible |
| $\bar{Q}_{I_1}(ROI_1)$ | 0.07 | 0.50 (+0.43) |
| $\bar{Z}_{I_1}(ROI_1)$ | -0.42 | 0.07 (+0.49) |
| $\bar{Z}_{I_{BF}}(ROI_1)$ | -0.44 | -0.16(+0.38) |
| Qualitative | Not visible | Visible |
| $\bar{Q}_{I_T}(ROI_2)$ | 0.08 | 0.59(+0.51) |
| $\bar{Z}_{I_T}(ROI_2)$ | -0.63 | 0.22(+0.85) |
| $\bar{Z}_{I_{BF}}(ROI_2)$ | 0.13 | 0.98(+0.85) |
| Qualitative | Not visible | Visible |
| $\bar{Q}_{I_{12}}(ROI_3)$ | 0.51 | 0.94(+0.43) |
| $\bar{Z}_{I_{12}}(ROI_3)$ | 0.19 | 0.79(+0.80) |
| $\bar{Z}_{I_{BF}}(ROI_3)$ | -0.95 | -0.25(+0.70) |

CONCLUSIONS

In this paper we propose the application of a method to take objective observer independent measurement of the specific ^{123}I -mIBG uptake at any region of interest in reference to the SIOOPEN sector where it is located.

When response to treatment is light, low definition in scan may make impossible to the human eye to appreciate changes in the intensity. $\bar{Z}_{I_{BF}}(ROI_{\#})$, $\bar{Z}_{I_k}(ROI_{\#})$ and $\bar{Q}_{I_k}(ROI_{\#})$ measurements may assist in the application of SIOOPEN validated semi-quantitative scoring method as an additional tool for measuring and comparing ^{123}I -mIBG uptake in doubt cases in which differences in assessment between observers could appear.

$\bar{Z}_{I_{BF}}(ROI_{\#})$ is a measuring tool for absolute comparison between any regions and between patients and scans. It has an intuitive measurement of how much a region of interest stands out among the rest of the body. It enables to take objective measurements of uptake in a region in reference to the whole body frame counts average to precise the increase or decrease of uptake in that region in comparison with previous scans of the same or other patient.

$\bar{Q}_{I_k}(ROI_{\#})$ and $\bar{Z}_{I_k}(ROI_{\#})$ enable the objective comparison of the specific uptake measurements at different ROIs inside the same SIOOPEN sector. They are referenced to the local counts average at SIOOPEN sector k . $\bar{Q}_{I_k}(ROI_{\#})$ has shown an intuitive interpretation. It is close to 0.00 when the uptake at region is hardly visible. As uptake increases, the peak is more visible and $\bar{Q}_{I_k}(ROI_{\#})$ increases accordingly taking values lower than 0.40 when is not intense and higher than 0.40 when it is a very intense peak. At limbs, the significance of $\bar{Q}_{I_k}(ROI_{\#})$ is slightly different, that is, values close to 0.40 of any ROI are due to peaks more intense (and abnormal) at trunk than in limbs, where uptake peaks reach higher $\bar{Q}_{I_k}(ROI_{\#})$ values.

$\bar{Q}_{I_k}(ROI_{\#})$ greater than 0.40 is a good candidate to automatically detect abnormal uptake in head and trunk sectors. That is, any region in sector with $\bar{Q}_{I_k}(ROI_{\#})$ greater than 0.40 has a high abnormal uptake value and is very likely to be an abnormal uptake peak. But, in limb sectors, due to the low counts average, there are always regions with values greater than 0.40 although they are not visible (they are not abnormal peaks).

In such sectors, for automatic detection, the values of $\bar{Z}_{I_{BF}}(ROI_{\#})$ should be used because it is referenced to whole body counts average \bar{I}_{BF} . At any sector, a region with a value $\bar{Q}_{I_{BF}}(ROI_{\#})$ greater than 0.40 could be automatically identified as abnormal.

ACKNOWLEDGMENTS

This work has been supported by “Ayudas para Actividades Preparatorias de Proyectos Coordinados entre Investigadores de la Universitat Politècnica de València e Investigadores del Hospital Universitario y Politécnico La Fe”, II Call, 2013, AUTOSCOREMIBG project. The authors are very grateful to the referees for their useful comments.

REFERENCES

- Ady N, Zucker J, Asselain B, Edeline V, Bonnin F, Michon J, Gongora R, Manil L (1995). A new ^{123}I -mibg whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage iv neuroblastoma. *Eur J Cancer* 31A:256–61.
- Bombardieri E, Giammarile F, Aktolun C, Baum R, Delaloye A, Maffioli L, *et al.* (2010). ^{131}I / ^{123}I -metaiodobenzylguanidine (mibg) scintigraphy procedures guidelines for tumour imaging. *Eur J Nucl Med Mol I* 37:2436–46.
- Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, *et al.* (2011). Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the international neuroblastoma risk group project. *Radiology* 261:243–57.
- Bulten B, van der Palen R, van Laarhoven H, Kapusta L, Mavinkurve-Groothuis A, de Geus-Oei L (2012). Interobserver variability of heart-to-mediastinum ratio in ^{123}I -mibg sympathetic imaging. *Eur J Nucl Med Mol I* 39:S508.
- Charron M (2013). Contemporary approach to diagnosis and treatment of neuroblastoma. *Q J Nucl Med Mol Im* 57:40–52.
- Chen W, Cao Q, Dilsizian V (2011). Variation of heart-to-mediastinal ratio in ^{123}I -mibg cardiac sympathetic imaging: its affecting factors and potential corrections. *Curr Cardiol Rep* 13:132–7.
- Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, *et al.* (2013). Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: Results of the cologne interscore comparison study. *J Clin Oncol* 31:944–51.
- Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S, *et al.* (2000). Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. the sfop group. *Med Pediatr Oncol* 34:237–41.
- Hannequin P, Mas J (2002). Statistical and heuristic image noise extraction (shine): a new method for processing

- poisson noise in scintigraphic images. *Phys Med Biol* 47:4329–44.
- Inoue Y, Abe Y, Itoh Y, Asano Y, Kikuchi K, Sakamoto Y, *et al.* (2013). Acquisition protocols and correction methods for estimation of the heart-to-mediastinum ratio in ¹²³I-metaiodobenzylguanidine cardiac sympathetic imaging. *J Nucl Med* 54:707–13.
- Jeong CB, Kim KG, Kim TS, Kim SK (2011). Comparison of image enhancement methods for the effective diagnosis in successive whole-body bone scans. *J Digit Imaging* 24:424–36.
- Jia-Yann H, Pan-Fu K, Yung-Sheng C (2007). A set of image processing algorithms for computer-aided diagnosis in nuclear medicine whole body bone scan images. *IEEE T Nucl Sci* 54:514–22.
- Krom AJ, Wickham F, Hall ML (2013). Evaluation of image enhancement software as a method of performing half-count bone scans. *Nucl Med Commun* 34:78–85.
- Ladenstein R, Poetschger U, Boubaker A, Bar-Sever Z, Drake B, Staudenherz A, *et al.* (2011). The prognostic value of semi-quantitative I-123 MIBG scintigraphy at diagnosis in high risk neuroblastoma: validation of the SIOPEN score method. *Pediatr Blood Cancer* 57:732–3.
- Lewington V, Poetschger U, Boubaker A, Bar-Sever Z, Drake B, Staudenherz A, *et al.* (2011). The prognostic value of semi-quantitative I-123 MIBG scintigraphy at diagnosis in high-risk neuroblastoma: Validation of the SIOPEN score method. *J Clin Oncol* 29:(suppl; abstract 9511).
- Lewington V, Sever ZB, Lynch T, Giammarile F, McEwan A, Shulkin B, *et al.* (2009). Development of a new, semiquantitative I-123 MIBG reporting method in high risk neuroblastoma. *Eur J Nucl Med Mol I* 50:1379.
- Maisey M, Natarajan T, Hurley P, Jr HW (1973). Validation of a rapid computerized method of measuring ^{99m}Tc pertechnetate uptake for routine assessment of thyroid structure and function. *J Clin Endocrinol Metab* 36:317–22.
- Martínez-Díaz R, Balaguer J, Sánchez-Ruiz LM, Bello P, Castel V, Perís-Fajarnés G (2013). On analytical methods in neuroblastoma detection. *Abstr Appl Anal* 2013:341346.
- Matthay K, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, *et al.* (2010). Criteria for evaluation of disease extent by ¹²³I-metaiodobenzylguanidine scans in neuroblastoma: a report for the international neuroblastoma risk group (inrg) task force. *Brit J Cancer* 102:1319–26.
- Messina J, Cheng S, Franc B, Charron M, Shulkin B, To B, *et al.* (2006). Evaluation of semiquantitative scoring system for metaiodobenzylguanidine (mibg) scans in patients with relapsed neuroblastoma. *Pediatr Blood Cancer* 47:865–74.
- Mueller W, Coppenrath E, Pfluger T (2013). Nuclear medicine and multimodality imaging of pediatric neuroblastoma. *Pediatr Radiol* 43:418–27.
- Sajn L, Kukar M, Kononenko I, Milcinski M (2005). Computerized segmentation of whole-body bone scintigrams and its use in automated diagnostics. *Comput Meth Prog Bio* 80:47–55.
- Sharp S, Parisi M, Gelfand M, Yanik G, Shulkin B (2013). Functional-metabolic imaging of neuroblastoma. *Q J Nucl Med Mol Im* 57:6–20.
- Wesolowski C, Yahil A, Puetter R, Babyn P, Gilday D, Khan M (2005). Improved lesion detection from spatially adaptive, minimally complex, pixon reconstruction of planar scintigraphic images. *Comput Med Imag Grap* 29:65–81.
- Yanik GA, Parisi MT, Shulking BL, Naranjo A, Kreissman SG, London WB, *et al.* (2013). Semiquantitative mibg scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the children's oncology group. *J Nucl Med* 54:541–8.
- Yin T, Chiu N (2004). A computer-aided diagnosis for locating abnormalities in bone scintigraphy by a fuzzy system with a three-step minimization approach. *IEEE T Med Imaging* 23:639–54.